ARCUTIS BIOTHERAPEUTICS INC (ARQT)
Sector: Health Care
2026 Annual Meeting Analysis
ARCUTIS BIOTHERAPEUTICS INC · Meeting: June 5, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Three Class III Directors to Hold Office Until the 2029 Annual Meeting of Stockholders
Heron has served since 2016 and has extensive biotech investing experience; ARQT's 3-year return of +67.4% trails XBI (SPDR S&P Biotech ETF) by only 1.4 percentage points, well below the 65-point threshold required to trigger a vote against under the strong-positive TSR tier, so no TSR concern applies, and no overboarding, attendance, or independence issues were identified.
Krishnamohan joined in September 2022 (less than 24 months before the April 2024 cutoff would have applied, but she joined more than 24 months ago as of the 2026 meeting), and the TSR gap of -1.4pp versus XBI (SPDR S&P Biotech ETF) is far below the 65-point trigger threshold; she serves on the Audit Committee and is designated an audit committee financial expert with relevant CFO-level biotech experience, and no other policy concerns were identified.
Watanabe is the CEO and a director; as an executive director he is subject to the same TSR trigger as other directors, but ARQT's 3-year return of +67.4% trails XBI (SPDR S&P Biotech ETF) by only 1.4 percentage points, far short of the 65-point threshold required to trigger an against vote under the strong-positive TSR tier, so no TSR concern applies, and his Say on Pay vote determination is separately assessed in Proposal 3.
All three Class III director nominees — Heron, Krishnamohan, and Watanabe — pass all policy screens. ARQT's 3-year stock return of +67.4% is nearly in line with the XBI (SPDR S&P Biotech ETF) benchmark at +68.8%, with a gap of only -1.4 percentage points, well below the 65-point threshold needed to trigger an against vote for directors under the strong-positive TSR tier. No overboarding, independence, attendance, or qualifications concerns were identified for any nominee.
Say on Pay
✓ FORCEO
Todd Franklin Watanabe
Total Comp
$7,223,065
Prior Support
84.68%%
The prior Say on Pay vote received approximately 84.68% shareholder support at the 2025 annual meeting, well above the 70% threshold that would require visible remediation efforts. The CEO's total compensation of $7,223,065 is within a reasonable range for a CEO of a commercial-stage biotech company with approximately $2.9 billion in market cap and 123% revenue growth in 2025; the pay mix is heavily weighted toward variable, at-risk compensation (90% for the CEO per the proxy), which satisfies the policy's requirement that at least 50-60% of senior executive pay be performance-based. The company's corporate goals were scored at 125% of target reflecting genuine business achievement including $372 million in product revenue, and a meaningful clawback policy compliant with Nasdaq and SEC requirements is in place.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
7 yrs
Audit Fees
$1,937,370
Non-Audit Fees
$181,482
EY has served as auditor since 2019 (approximately 7 years), well below the 25-year tenure threshold that would raise independence concerns; non-audit fees (tax fees of $177,882 plus other fees of $3,600, totaling $181,482) represent approximately 9.4% of audit fees of $1,937,370, comfortably below the 50% threshold; and no material financial restatements were identified, so all policy screens are passed.
Overall Assessment
The 2026 Arcutis Biotherapeutics annual meeting presents three standard proposals: election of three Class III directors, ratification of Ernst & Young as auditor, and an advisory vote on executive compensation. All three proposals pass applicable policy screens and receive FOR vote determinations, supported by near-benchmark TSR performance versus XBI (SPDR S&P Biotech ETF), clean auditor fee ratios, strong prior Say on Pay support of nearly 85%, and a pay program that heavily emphasizes at-risk variable compensation aligned with demonstrated business results.